Heme is crucial for medium-dependent metronidazole resistance in clinical isolates of C. difficile
Journal of Antimicrobial Chemotherapy(2020)
摘要
Until recently, metronidazole was the first-line treatment for Clostridioides difficile infection and it is still commonly used. Though resistance has been reported due to the plasmid pCD-METRO, this does not explain all cases. Here, we investigate resistance to metronidazole in a collection of clinical isolates of C. difficile . We find that nearly all isolates demonstrate a heme-dependent increase in the minimal inhibitory concentration for metronidazole, which in some cases leads to isolates being qualified as resistant (MIC > 2 mg/L). Moreover, whole genome sequence analysis reveals a single nucleotide polymorphism in the heme responsive gene hsmA , which defines a metronidazole resistant lineage of PCR ribotype 010 / multilocus sequence type 15 isolates that also includes pCD-METRO containing strains. Together our data demonstrate that heme is crucial for medium-dependent metronidazole resistance in C. difficile .
### Competing Interest Statement
The COMBACTE-CDI consortium includes partners GSK, Pfizer, DaVolterra, AstraZeneca, Sanofi Pasteur and bioMerieux. The companies did not have a role in the design and execution of the experiments for this study but provided the WGS of the isolates (GSK) and allowed examination of the FASTQ files (bioMerieux).
更多查看译文
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要